DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
What will happen during the trial?
Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 1,100 patients (estimated)
- Sponsors
- Southwest Oncology Group
- Collaborators
- National Cancer Institute (NCI), Janssen Research & Development LLC
- Tags
- Monoclonal Antibody, CD38, Maintenance, Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1019
- NCT Identifier
- NCT04071457
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.